TherapeuticsMD (TXMD) Income towards Parent Company (2010 - 2026)
TherapeuticsMD (TXMD) posted Income towards Parent Company of -$8000.0 for Q1 2026, down 14.29% on a QoQ basis from -$7000.0 in Q4 2025, and up 52.94% year-over-year from -$5230.8 in Q1 2025.
TherapeuticsMD (TXMD) Income towards Parent Company (2010 - 2026) Analysis & Trends
TherapeuticsMD's Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$8000.0 for Q1 2026.
- Quarterly Income towards Parent Company rose 52.94% year-over-year to -$8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93000.0 (up 138.46% YoY) and the FY2025 annual result came in at $84000.0, down 35.88% from the prior year.
- Income towards Parent Company was -$8000.0 for Q1 2026 at TherapeuticsMD, down from -$7000.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $127.2 million in Q2 2022 and bottomed at -$31.1 million in Q1 2022.
- A 5-year average of $6.8 million and a median of -$7500.0 in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company soared 398.12% — and 2025, when it sank 122.67%.
- TherapeuticsMD's Income towards Parent Company stood at $29.2 million in 2022, then slumped by 97.75% to $658000.0 in 2023, then tumbled by 79.03% to $138000.0 in 2024, then slumped by 105.07% to -$7000.0 in 2025, then dropped by 14.29% to -$8000.0 in 2026.
- Business Quant data shows TXMD's Income towards Parent Company at -$8000.0 in Q1 2026, -$7000.0 in Q4 2025, and $102000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.18 Bn | 785.00 Mn |
| 10 | TherapeuticsMD | 284,239.99 | -8.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -40,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 658,000.00 |
| Sep 30, 2023 | -1.94 Mn |
| Mar 31, 2023 | -1.29 Mn |
| Dec 31, 2022 | 29.25 Mn |
| Sep 30, 2022 | -14.33 Mn |
| Jun 30, 2022 | 127.15 Mn |
| Mar 31, 2022 | -31.15 Mn |
| Dec 31, 2021 | 50.15 Mn |
| Sep 30, 2021 | -47.42 Mn |
| Jun 30, 2021 | -42.65 Mn |
| Mar 31, 2021 | -39.38 Mn |